Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCKDK | O14874 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14293108 | 0.87 | BCKDK (0.58) | BCKDKRAB9AKDM4ESENP1MCL1 | |
| SCHEMBL2279755 | 0.87 | BCKDK (0.77) | BCKDKRAB9AKDM4ESENP1MCL1 | |
| SCHEMBL8877598 | 0.83 | MCL1 (0.56) | BCKDKRAB9AKDM4EMCL1SMN1; SMN2 | |
| SCHEMBL13659612 | 0.83 | BCKDK (0.54) | BCKDKRAB9AKDM4ESENP1MCL1 | |
| SCHEMBL1254412 | 0.80 | MCL1 (0.51) | BCKDKRAB9AKDM4EMCL1SMN1; SMN2 | |
| SCHEMBL3063440 | 0.79 | BCKDK (0.49) | BCKDKRAB9AKDM4ESENP1MCL1 | |
| SCHEMBL1447569 | 0.79 | PRNP (0.60) | RAB9AKDM4ESMN1; SMN2NPC1TSHR | |
| SCHEMBL3067147 | 0.78 | MCL1 (0.41) | BCKDKRAB9AMCL1SMN1; SMN2NPC1 | |
| SCHEMBL12581557 | 0.78 | MCL1 (0.41) | BCKDKRAB9AKDM4EMCL1SMN1; SMN2 | |
| SCHEMBL12553241 | 0.78 | MCL1 (0.41) | BCKDKRAB9AKDM4EMCL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409880-B2 | Modulators of TLR3/dsRNA complex and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409880-B2 | Modulators of TLR3/dsRNA complex and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-08-09 | — | — | US | disclosed |
| US-9409880-B2 | Modulators of TLR3/dsRNA complex and uses thereof | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2848614-A2 | Acrylamide derivatives as antibiotic agents | Debiopharm International SA (CH) | 2015-03-18 | — | — | EP | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2014-04-17 | — | — | US | disclosed |
| EP-2665708-A2 | MODULATORS OF TLR3/DSRNA COMPLEX AND USES THEREOF | The Regents of the University of Colorado, A Body Corporate (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8450307-B2 | Therapeutic agents, and methods of making and using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2013-05-28 | — | — | US | disclosed |
| WO-2012099785-A2 | MODULATORS OF TLR3/DSRNA COMPLEX AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012099785-A2 | MODULATORS OF TLR3/DSRNA COMPLEX AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | BERMAN JUDD M (CA) | 2012-01-12 | — | — | US | disclosed |
| US-7879872-B2 | comprising (E)-N-methyl-N-(3-methylbenzofuran-2-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide or pharmaceutically acceptable salts thereof; and gentamicin; wherein combination has an fractional inhibitory coconcentration index value of 0.3 against S. aureus 29213 | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | DEBIOPHARM INTERNATIONAL SA (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093705-A1 | Therapeutic agents, and methods of making and using the same | MCL1, DHFR, ANXA5 | BCKDK 1986/4885RAB9A 2777/4885KDM4E 4494/4885 |
| US-20120010127-A1 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same | DBI, SERPINB1, CTSF | BCKDK 2182/4885RAB9A 2755/4885KDM4E 4139/4885 |
| US-20140107106-A1 | THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME | MCL1, DHFR, ANXA5 | BCKDK 1986/4885RAB9A 2777/4885KDM4E 4494/4885 |
| US-20060142265-A1 | Compositions comprising multiple bioactive agents, and methods of using the same | DBI, SERPINB1, CTSF | BCKDK 2182/4885RAB9A 2755/4885KDM4E 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.